On a November day in 2025, a small rare-disease drugmaker in Deer Park, Illinois, laid out its third-quarter ledger, and the story it told was one of two faces. Product sales climbed 129 percent to $22.5 million, the nineteenth straight quarter of sequential growth, yet the company still posted a GAAP loss while the costs of handing its INCRELEX distribution abroad weighed on margins. It is the familiar arc of a young company growing into its own ambitions, where the gain arrives first and the price of transition is paid in the same breath.
Eton Pharmaceuticals Posts 129% Q3 Product Sales Growth as ET-600 Heads Toward February 2026 FDA Decision
Nineteen straight quarters of sequential growth, but still a net loss
Mark
Sales more than doubled, yet the company lost money. How does that fit together?
Mimi
Mostly the INCRELEX handover in Europe. Eton paid $1.4 million in commissions to Ipsen and sold $1.9 million of finished inventory as part of the transition, and those costs hit cost of goods sold. Adjusted gross margin fell to 45% from 64%.
Luke
Worth noting that's the company's framing. The adjusted figures strip out items like inventory step-up and amortization, so the GAAP loss of $1.9 million is the plainer number.
Mark
And the forecast of a 70% margin in Q4?
Luke
That's guidance, not a result. It depends on transition costs falling as promised.
Mimi
The company says marketing authorizations have moved in key European countries and costs end by mid-2026.
Mark
Is all of the revenue repeatable?
Mimi
Not entirely. $0.9 million is expected to be non-recurring. The $2.4 million Esteve loading order may repeat, since a supply agreement expects annual or semi-annual purchases.
Luke
Expects, not guaranteed. Also, the 1,000-patient U.S. estimate for INCRELEX only applies if the EU definition is adopted, and the FDA hasn't weighed in yet.
Mark
What's the nearest hard date?
Mimi
February 25, 2026, the ET-600 PDUFA date. Luke would remind us acceptance for review isn't approval.
Luke
Right. And KHINDIVI's early-2027 approval is only a projection built on an FDA review timeline.
Il Polso
- Product sales surged 129% to $22.5 million, yet a GAAP loss of $0.07 per share kept the quarter from being a clean victory.
- Gross margin fell to about 45% as the handover of ex-U.S. INCRELEX distribution to Ipsen and Esteve drained profit through commissions and inventory sales.
- Eton is steering toward a fourth-quarter margin near 70%, with transition costs expected to fade and end by mid-2026.
- All eyes now turn to December's FDA feedback on INCRELEX, the January start of the KHINDIVI bioequivalence study, and the February 25 PDUFA date for ET-600.
On a November day in 2025, a small rare-disease drugmaker in Deer Park, Illinois, laid out its third-quarter ledger, and the story it told was one of two faces. Product sales climbed 129 percent to $22.5 million, the nineteenth straight quarter of sequential growth, yet the company still posted a GAAP loss while the costs of handing its INCRELEX distribution abroad weighed on margins. It is the familiar arc of a young company growing into its own ambitions, where the gain arrives first and the price of transition is paid in the same breath.
Eton Pharmaceuticals, a rare-disease company in Deer Park, Illinois, reported third-quarter results on November 6, 2025, and its headline number was striking: product sales of $22.5 million, up 129 percent from a year earlier. It marked the nineteenth consecutive quarter of sequential growth. Growth came from ALKINDI SPRINKLE, Carglumic Acid, and two recently acquired brands, INCRELEX and GALZIN, with INCRELEX the largest contributor. GALZIN, which treats Wilson disease, passed its year-end goal of 200 active patients.
The profit picture was less clean. Eton posted a GAAP net loss of $1.9 million, or $0.07 per share, though Adjusted EBITDA reached $2.9 million. Margins were squeezed by the transfer of ex-U.S. INCRELEX distribution to Ipsen and Esteve, which brought commissions, inventory sales, and an initial loading order that together weighed heavily on cost of goods. Adjusted gross margin fell to 45 percent from 64 percent a year earlier. Management expects transition costs to drop sharply in the fourth quarter, end by mid-2026, and guides to an adjusted gross margin of about 70 percent in Q4.
Operating costs rose with the launch push, as advertising, promotion, stock compensation, and new hires lifted general and administrative expense. Eton is betting that the spending will pay off in the pipeline. The FDA accepted the ET-600 application with a PDUFA date of February 25, 2026, and a first-quarter launch aimed at pediatric endocrinology is being prepared. For KHINDIVI, the FDA signaled openness to a wider age range, pending a bioequivalence study due to start by January 2026.
CEO Sean Brynjelsen called 2025 a transformational year. The dates that will show whether that word holds are December's INCRELEX feedback, January's KHINDIVI study start, and February 25 for ET-600.
Eton Pharmaceuticals, a rare-disease drug company based in Deer Park, Illinois, reported its third-quarter results on November 6, 2025, and the headline number was product sales of $22.5 million. That is 129% above the same quarter a year earlier, and it marks the nineteenth consecutive quarter in which product sales rose from the one before. The company, listed on Nasdaq as ETON, scheduled a conference call for 4:30 p.m. Eastern the same day.
The profit picture was more mixed. Eton posted a net loss of $1.9 million, or $0.07 per share, against net income of $0.6 million, or $0.02 per share, a year earlier. On a non-GAAP basis, diluted earnings were $0.04 per share, and Adjusted EBITDA was $2.9 million, up from $2.0 million. The company generated $12.0 million in cash from operations during the quarter. Total net revenue was $22.5 million, up 118% from $10.3 million; net product revenue was up 129% from $9.8 million.
Growth came from two directions. ALKINDI SPRINKLE and Carglumic Acid grew strongly, and two recently acquired brands, INCRELEX and GALZIN, added revenue. INCRELEX was the largest contributor in the quarter. Eton says the product is tracking ahead of expectations after its relaunch, and it is pushing education on severe primary IGF-1 deficiency, which it believes is underdiagnosed. The U.S. definition of the condition covers roughly 200 patients; under the broader European Union definition, the company estimates about 1,000. Eton has asked the FDA for a meeting and submitted a proposed study design, expects feedback in December, and could start a study in the first half of 2026 if that is favorable.
GALZIN, acquired in December 2024 and relaunched in March 2025, treats Wilson disease. Uptake accelerated in the third quarter, and the company says it passed its prior year-end goal of 200 active patients. Eton was a top sponsor of the Wilson Disease Association Annual Summit.
Margins were where the quarter got complicated. Gross profit was $7.9 million, up 25% from $6.3 million. Adjusted gross profit was $10.2 million, a 45% margin, compared with $6.6 million and 64% a year ago. The company blamed costs from moving ex-U.S. distribution of INCRELEX to Ipsen and Esteve. Within cost of goods sold, $1.4 million was sales commissions to Ipsen for transition services, $1.9 million was finished inventory sold to Ipsen and Esteve, and $4.1 million came from an initial loading order of semi-finished goods to Esteve. That order also produced $2.4 million in revenue, and a further $0.9 million of product revenue from inventory sales and transition services is expected not to recur. Eton expects transition costs to drop sharply in the fourth quarter and end by mid-2026, and it guides to an adjusted gross margin of about 70% in Q4.
Operating costs rose. Research and development was $1.1 million versus $0.5 million, driven by the ET-700 and ET-800 programs. General and administrative expense was $8.1 million versus $5.3 million, reflecting advertising, launch promotion, stock compensation and added headcount. Adjusted G&A was $6.9 million, up from $4.3 million, and the company expects it to stay flat or fall in the fourth quarter.
The pipeline carries the next milestones. The FDA accepted the ET-600 new drug application in July and set a PDUFA action date of February 25, 2026. Eton has scheduled launch inventory production for the fourth quarter, is running pre-launch marketing, and is eyeing a first-quarter 2026 launch aimed at pediatric endocrinology. For KHINDIVI, currently approved for ages five and up, an FDA meeting in September produced openness to widening the age range, with a bioequivalence study requested for a revised formulation. That study is due to start by January 2026, with a supplemental application in the second quarter of 2026 and a 10-month review pointing to possible approval in early 2027. The ET-700 pilot PET study is to begin in the first quarter of 2026, with results expected mid-year.
"2025 has been a transformational year for Eton," CEO Sean Brynjelsen said. The dates to watch are December's INCRELEX feedback, January's KHINDIVI study start, and February 25 for ET-600.
Citazioni salienti
2025 has been a transformational year for Eton.— Sean Brynjelsen, CEO, Eton Pharmaceuticals
Vuoi la storia completa?
Leggi l'originale su The Manila Times ↗
Health & Medicine